Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Innovative Sutureless Fabrication Strategy for Tissue-Engineered Pediatric Heart Valves Using an Evolutive Support System.

Rioux Y., Fradette J., Hayward CJ., Séguin V., Maciel Y., Bégin-Drolet A.

Laboratory Study on Systemic / IV, published in Ann Biomed Eng (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Ann Biomed Eng (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42521966
DOI
10.1007/s10439-026-04303-6

Abstract (original English)

Current pediatric heart valve protheses lack growth potential, leading to repeated surgeries and long-term complications. Tissue-engineered heart valves (TEHVs), composed of living tissue, offer the ability to remodel and may accommodate somatic growth. This study introduces a sutureless fabrication strategy for TEHV designed to eliminate suture-related weak points and preserve valve geometry during in vitro maturation through a novel evolutive support system. This system was used to form and maintain the geometry of a fibrin-based valve scaffold embedded with human adipose-derived stromal cells during in vitro culture by mechanically constraining tissue contraction in all directions except thickness. Dimensional analysis confirmed geometry preservation throughout 28 days of perfusion bioreactor culture. At the end of the culture period, the matured valve was released from the evolution support system, after which the valve contracted to stable dimensions of approximately 16 mm in diameter, 23 mm in height, and 400 µm in thickness, corresponding to reductions of 26%, 43%, and 84% in diameter, height, and thickness, respectively, relative to the initial molded geometry. These ratios provide critical design guidance for pediatric target dimensions. Cell viability exceeded 90% upon molding, and cell density increased nearly 100-fold during culture. Histology revealed progressive c

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research